Etanercept is a recombinant soluble tumour necrosis factor alpha receptor administered subcutaneously at the dose of 50 mg weekly (or 25 mg/twice weekly) for the treatment of the main chronic arthritides: rheumatoid arthritis and spondyloarthropathies. It shows high qualities in terms of efficacy and manageability. Favourable results were reported in all localisations of spondyloarthropathies: axial disease, peripheral arthritis, and enthesitis. In particular, several studies demonstrated its efficacy on the clinical and functional indicators of ankylosing spondylitis. Similar data were also reported for psoriatic arthritis in which, in addition, a significant reduction in the progression of erosive damages was widely described. Furthermore, although only a few studies are available, very interesting results have been obtained in patients suffering from undifferentiated spondyloarthropathies and severe enthesitis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Association between resolution of MRI-detected inflammation and improved clinical outcomes in axial spondyloarthritis under long-term anti-TNF therapy.
RMD Open
January 2025
Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Charite Universitatsmedizin Berlin, Berlin, Germany.
Objectives: In this post-hoc analysis of ESTHER trial, we aimed to investigate the longitudinal relationship between inflammation on MRI and the achievement of inactive disease/low disease activity in patients with axial spondyloarthritis (axSpA) treated with long-term tumor necrosis factor (TNF) inhibitor etanercept.
Methods: Of the 76 patients with active axSpA in the ESTHER trial, we included all patients treated with etanercept for at least 6 months for main analysis. All clinical and MRI data from 4.
The relationship between drug-induced immunogenicity and hypersensitivity reactions and skin tests related to infliximab, etanercept and adalimumab in patients with rheumatoid arthritis and ankylosing spondylitis.
Turk J Med Sci
December 2024
Division of Clinical Immunology and Allergy, Department of Chest Diseases, Faculty of Medicine, Ankara University, Ankara, Turkiye.
Article Synopsis
- The study aimed to explore the connection between serum antidrug antibodies (ADAbs), hypersensitivity reactions, and local injection site reactions in patients with ankylosing spondylitis and rheumatoid arthritis who were on anti-TNF treatments.
- Sixty-nine patients with ankylosing spondylitis and 46 with rheumatoid arthritis were evaluated, measuring their drug levels, disease activity scores, and conducting skin tests to assess hypersensitivity.
- Results indicated a significant link between hypersensitivity reactions (both immediate and local) and the intradermal tests in patients taking anti-TNF drugs, particularly with adalimumab and etanercept.
New onset heart failure in adolescents with inflammatory joint disease treated with TNF-α inhibitors: a case-based review.
Rheumatol Int
December 2024
Division of Pediatric Rheumatology, Department of Pediatrics, Attikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
The safety of tumor necrosis factor (TNF) inhibitors has been demonstrated for over two decades. However, their effects on cardiovascular function in patients with rheumatic diseases remain controversial, and conclusions are additionally hampered by the cardiovascular complications inherent in such diseases. We present two 15-year-old patients diagnosed with ankylosing spondylitis and juvenile idiopathic arthritis classified as polyarthritis with positive rheumatoid factor, respectively.
View Article and Find Full Text PDFAn Uncommon Overlap Syndrome Between Ankylosing Spondylitis and Amyotrophic Lateral Sclerosis-Case Report.
Medicina (Kaunas)
October 2024
Department of Internal Medicine IV, Faculty of Medicine, "Victor Babes" University of Medicine and Pharmacy, 2 Eftimie Murgu, 300041 Timisoara, Romania.
This case report describes an uncommon overlap syndrome between ankylosing spondylitis (AS) and amyotrophic lateral sclerosis (ALS). Initially, the patient was diagnosed with AS, for which he received various specific treatments, including TNF-α inhibitors. After five years of treatment with TNF-α inhibitor etanercept, the patient was referred for a full neurological assessment after he reported balance disturbances, postural instability, muscle weakness, and other neurological symptoms that indicated the presence of a neurological disorder.
View Article and Find Full Text PDFTreatment of Reactive Arthritis with Biological Agents.
Curr Rheumatol Rep
December 2024
Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India.
Article Synopsis
- The review examines whether biologic therapies are effective for treating reactive arthritis (ReA), an inflammatory joint condition caused by infections.
- Recent studies highlight that biologics like anti-TNF agents, anti-IL17, and anti-IL6 are effective and generally safe for patients with refractory ReA, showing significant clinical improvement.
- The authors emphasize the necessity for controlled trials to enhance the scientific understanding and clinical decision-making for patients not responding to standard treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!